MA71624A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents

Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Info

Publication number
MA71624A
MA71624A MA71624A MA71624A MA71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A
Authority
MA
Morocco
Prior art keywords
parp14
therapy
protein degradation
targeted protein
targeted
Prior art date
Application number
MA71624A
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Nicholas Robert Perl
Jennifer DOWNING
Original Assignee
Abbvie Operations Singapore Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Operations Singapore Pte. Ltd. filed Critical Abbvie Operations Singapore Pte. Ltd.
Publication of MA71624A publication Critical patent/MA71624A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA71624A 2022-07-29 2023-07-28 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie MA71624A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263393522P 2022-07-29 2022-07-29
US202263420307P 2022-10-28 2022-10-28
US202363443170P 2023-02-03 2023-02-03
PCT/US2023/028955 WO2024026081A1 (fr) 2022-07-29 2023-07-28 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
EP23758760.5A EP4561999A1 (fr) 2022-07-29 2023-07-28 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Publications (1)

Publication Number Publication Date
MA71624A true MA71624A (fr) 2025-05-30

Family

ID=87797850

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71624A MA71624A (fr) 2022-07-29 2023-07-28 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Country Status (13)

Country Link
US (1) US20240101540A1 (fr)
EP (1) EP4561999A1 (fr)
JP (1) JP2025526433A (fr)
KR (1) KR20250055509A (fr)
CN (1) CN119923391A (fr)
AU (1) AU2023312809A1 (fr)
CA (1) CA3262703A1 (fr)
CO (1) CO2025002261A2 (fr)
IL (1) IL318518A (fr)
MA (1) MA71624A (fr)
MX (1) MX2025001060A (fr)
TW (1) TW202417435A (fr)
WO (1) WO2024026081A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508568A (zh) 2023-04-07 2025-03-01 瑞典商阿斯特捷利康公司 Irak4蛋白水解靶向嵌合體

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
WO2019126443A1 (fr) 2017-12-21 2019-06-27 Ribon Therapeutics Inc. Quinazolinones en tant qu'inhibiteurs de parp14
AU2019251151B2 (en) * 2018-04-09 2022-07-07 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
JP2022537349A (ja) 2019-06-19 2022-08-25 ライボン・セラピューティクス・インコーポレイテッド 療法に使用するためのparp14の標的タンパク質分解

Also Published As

Publication number Publication date
KR20250055509A (ko) 2025-04-24
IL318518A (en) 2025-03-01
CN119923391A (zh) 2025-05-02
CA3262703A1 (fr) 2024-02-01
AU2023312809A1 (en) 2025-02-06
US20240101540A1 (en) 2024-03-28
EP4561999A1 (fr) 2025-06-04
JP2025526433A (ja) 2025-08-13
CO2025002261A2 (es) 2025-03-27
MX2025001060A (es) 2025-05-02
WO2024026081A1 (fr) 2024-02-01
TW202417435A (zh) 2024-05-01

Similar Documents

Publication Publication Date Title
MA56513A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
MA55511A (fr) Inhibiteurs de protéine tyrosine phosphatase
PT3990005T (pt) Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria
MA71624A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
PL3999119T3 (pl) Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
EP4221715A4 (fr) Thérapie anti-inflammatoire périvasculaire pour thrombose veineuse
EP4067495A4 (fr) Construction d'arnm pour l'expression de protéines et utilisation associées
EP4497062A4 (fr) Prédiction de branche dépendante de la charge
IL307902A (en) Microdystrophin gene therapy administration for treatment of dystrophinopathies
EP4004024A4 (fr) Domaines protéiques multimères pour la multifonctionnalité et la sécrétion améliorée de protéines thérapeutiques
JP1778652S (ja) マッサージ器
MA71618A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
EP3923911A4 (fr) Utilisation de compositions topiques d'inhibiteur de braf pour le traitement d'une radiodermatite
IL308290A (en) Ionic liquid formulations for treating inflammatory and autoimmune diseases
EP4313117A4 (fr) Utilisation de polypeptides adnf en thérapie
EP4282874A4 (fr) Peptide pour prévenir et traiter la fibrose
PL4034661T3 (pl) Wektory aav typu „wszystko w jednym” do leczenia chorób wywołanych koronawirusem
EP4003290C0 (fr) Stabilisation de protéines thérapeutiques avec des substances zwittérioniques de mise en mémoire tampon contenant de la pipérazine ou de la morpholine
EP4251757A4 (fr) Expression fondée sur une levure de protéines thérapeutiques in vivo
EP3807306A4 (fr) Séquence leader pour une expression plus élevée de protéines recombinées
PL4482481T3 (pl) Związki do zastosowania w leczeniu dystrofinopatii
EP4188433A4 (fr) Administration ciblée d'agents thérapeutiques
EP4463167A4 (fr) Ciblage de xkr8 dans des thérapies
HK40127146A (en) Targeted protein degradation of parp14 for use in therapy
HK40127147A (en) Targeted protein degradation of parp14 for use in therapy